Heikkinen Sanna, Koskenvuo Markku, Malila Nea, Sarkeala Tytti, Pukkala Eero, Pitkäniemi Janne
Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Unioninkatu 22, 00130, Helsinki, Finland.
Department of Public Health, Hjelt Institute, University of Helsinki, Mannerheimintie 172, PO Box 41, 00014, Helsinki, Finland.
Cancer Causes Control. 2016 Feb;27(2):249-58. doi: 10.1007/s10552-015-0702-5. Epub 2015 Dec 14.
Main aim was to estimate the association between use of exogenous hormones and breast cancer (BC) risk in a large population-based survey, and to assess the representativeness and overall validity of the data.
The survey 'Women's Health and Use of Hormones' was conducted in Finland in 2009, including 7,000 BC cases and 20,000 matched population controls. Conditional logistic regression was used to estimate odds ratios and their 95 % confidence interval. For validation, exposure prevalences were compared with population data from Statistics Finland and two large population-based surveys.
We found positive associations with BC risk and exclusive use of hormone-releasing intrauterine device (HR IUD) in postmenopausal women (1.48, 95 % CI 1.10-1.99), when compared to never-users of any hormonal contraceptive and considering only prediagnostic use in cases. Regarding use of other hormonal contraceptives (HC), a positive association between long HC use (≥2 years) and BC was observed in both groups, OR being 1.37 (95 % CI 1.12-1.68) for premenopausal and 1.11 (95 % CI 1.03-1.20) for postmenopausal women, when compared to never-users of other HC.
Observed association between HR IUD use and risk of BC in postmenopausal women is worrying and deserves further attention. Selection bias seemed not to explain this result. Considering the increasing popularity of HR IUD use in, e.g., USA, impact of possible adverse effects in public health could be significant.
在一项基于大规模人群的调查中,主要目的是评估外源性激素的使用与乳腺癌(BC)风险之间的关联,并评估数据的代表性和整体有效性。
2009年在芬兰开展了“女性健康与激素使用”调查,包括7000例乳腺癌病例和20000名匹配的人群对照。采用条件逻辑回归来估计比值比及其95%置信区间。为进行验证,将暴露患病率与芬兰统计局的人口数据以及两项基于大规模人群的调查进行了比较。
与从未使用过任何激素避孕方法的女性相比,仅考虑病例的诊断前使用情况时,我们发现绝经后女性中,激素释放宫内节育器(HR IUD)的单独使用与乳腺癌风险呈正相关(1.48,95%置信区间1.10 - 1.99)。关于其他激素避孕方法(HC)的使用,两组中均观察到长期使用HC(≥2年)与乳腺癌之间存在正相关,与从未使用过其他HC的女性相比,绝经前女性的比值比为1.37(95%置信区间1.12 - 1.68),绝经后女性为1.11(95%置信区间1.03 - 1.20)。
绝经后女性中观察到的HR IUD使用与乳腺癌风险之间的关联令人担忧,值得进一步关注。选择偏倚似乎无法解释这一结果。考虑到HR IUD在美国等国家的使用日益普遍,其可能的不良反应对公共卫生的影响可能很大。